

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 October 2008 (02.10.2008)

PCT

(10) International Publication Number
WO 2008/118468 A1

(51) International Patent Classification:

C07D 473/30 (2006.01) **A61K 31/52** (2006.01)
C07D 473/34 (2006.01) **A61P 29/00** (2006.01)
C07D 487/04 (2006.01) **A61P 35/00** (2006.01)
A61K 31/519 (2006.01)

SHIN, Youngsook; 64 Loop #22, Emeryville, California 94608 (US). **ZHANG, Dawei**; 3030 Blazing Star Drive, Thousand Oaks, California 91362 (US).

(21) International Application Number:

PCT/US2008/003962

(22) International Filing Date: 24 March 2008 (24.03.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/919,568 23 March 2007 (23.03.2007) US

(71) Applicant (for all designated States except US): **AMGEN INC.** [US/US]; M/s 28-2-c, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **CHEN, Yi**; 2727 Edison Street #209, San Mateo, California 94403 (US). **CUSHING, Timothy D.**; 1064 Glacier Avenue, Pacificia, California 94044 (US). **DUQUETTE, Jason A.**; 460 Bayview Avenue, Millbrae, California 94030 (US). **GONZALEZ LOPEZ DE TURISO, Felix**; 10 De Sabla Road #509, San Mateo, California 94402 (US). **HAO, Xiaolin**; 637 Sandy Hook Court, Foster City, California 94404 (US). **HE, Xiao**; 725 Crane Avenue, Foster City, California 94404 (US). **LUCAS, Brian**; 1836 Church Street, San Francisco, California 94131 (US). **MCGEE, Lawrence R.**; 39 Big Sur Way, Pacificia, California 94044 (US). **REICHEL, Andreas**; 6625 Pinnacle Way, Moorpark, California 93021 (US). **RZASA, Robert M.**; 160 Kennedy Avenue, Ventura, California 93003 (US). **SEGANISH, Jennifer**; 1825 Nash Drive, San Mateo, California 94401 (US).

(74) Agent: **PERSON, Richard V.**; Amgen Inc., M/s 28-2-c, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(54) Title: HETEROCYCLIC COMPOUNDS AND THEIR USES

(57) Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on, or associated with p110 activity, including but not restricted to leukemias, such as acute myeloid leukaemia (AML), myelo-dysplastic syndrome (MDS), myelo-proliferative diseases (MPD), chronic myeloid leukemia (CML), T-cell acute lymphoblastic leukaemia (T-ALL), B-cell acute lymphoblastic leukaemia (B-ALL), non Hodgkins lymphoma (NHL), B-cell lymphoma and solid tumors, such as breast cancer.

WO 2008/118468 A1